{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:16:18Z","timestamp":1792016178543,"version":"4.4.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,10]],"date-time":"2017-01-10T00:00:00Z","timestamp":1484006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ekir.2017.01.003","type":"journal-article","created":{"date-parts":[[2017,1,16]],"date-time":"2017-01-16T09:02:06Z","timestamp":1484557326000},"page":"442-450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":105,"title":["Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in\u00a0Patients With Autosomal Dominant Polycystic Kidney Disease"],"prefix":"10.1016","volume":"2","author":[{"given":"Ronald D.","family":"Perrone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad-Samer","family":"Mouksassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank S.","family":"Czerwiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene B.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berenice Y.","family":"Gitomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente E.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana C.","family":"Miskulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Broadbent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean F.","family":"Marier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2017.01.003_bib1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.2215\/CJN.00330705","article-title":"Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes","volume":"1","author":"Grantham","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.01.003_bib2","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/sj.ki.5002624","article-title":"Determinants of renal volume in autosomal-dominant polycystic kidney disease","volume":"73","author":"Grantham","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2017.01.003_bib3","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nrneph.2011.109","article-title":"Why kidneys fail in autosomal dominant polycystic kidney disease","volume":"7","author":"Grantham","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2017.01.003_bib4","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.01.003_bib5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1681\/ASN.2013040398","article-title":"Strategies targeting cAMP signaling in\u00a0the treatment of polycystic kidney disease","volume":"25","author":"Torres","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.01.003_bib6","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.trsl.2014.11.003","article-title":"Novel therapeutic approaches to autosomal dominant polycystic kidney disease","volume":"165","author":"LaRiviere","year":"2015","journal-title":"Transl Res"},{"key":"10.1016\/j.ekir.2017.01.003_bib7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1053\/j.ajkd.2009.04.029","article-title":"Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"54","author":"Levey","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2017.01.003_bib8","unstructured":"Food and Drug Administration, Center for Drug Evaluation and Research. Meeting of the Cardiovascular and Renal Drugs Advisory Committee (CRDAC). Available at: http:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/cardiovascularandrenaldrugsadvisorycommittee\/ucm364579.pdf. Accessed December 30, 2016."},{"key":"10.1016\/j.ekir.2017.01.003_bib9","unstructured":"US Food and Drug Administration. Biomarker Qualification\u00a0Program. Available at: http:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DrugDevelopmentToolsQualificationProgram\/ucm284076.htm. Accessed December 30, 2016."},{"key":"10.1016\/j.ekir.2017.01.003_bib10","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1053\/j.ajkd.2015.04.044","article-title":"Therapeutic area data standards for autosomal dominant polycystic kidney disease: a report from the Polycystic Kidney Disease Outcomes Consortium (PKDOC)","volume":"66","author":"Perrone","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2017.01.003_bib11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ekir.2017.01.003_bib12","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1001\/jama.2014.6634","article-title":"Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality","volume":"311","author":"Coresh","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2017.01.003_bib13","doi-asserted-by":"publisher","first-page":"e0132927","DOI":"10.1371\/journal.pone.0132927","article-title":"Predictors and the subsequent risk of end-stage renal disease - usefulness of 30% decline in estimated GFR over 2 years","volume":"10","author":"Chang","year":"2015","journal-title":"PLoS One"},{"issue":"suppl 1","key":"10.1016\/j.ekir.2017.01.003_bib14","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2017.01.003_bib15","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1515\/CCLM.2009.264","article-title":"Estimating glomerular filtration rate","volume":"47","author":"Miller","year":"2009","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.ekir.2017.01.003_bib16","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/biomet\/69.3.553","article-title":"A\u00a0class of rank test procedures for censored survival data","volume":"69","author":"Harrington","year":"1982","journal-title":"Biometrika"},{"key":"10.1016\/j.ekir.2017.01.003_bib17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.0006-341X.2000.00337.x","article-title":"Time-dependent ROC curves for censored survival data and a diagnostic marker","volume":"56","author":"Heagerty","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.ekir.2017.01.003_bib18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2215\/CJN.09500911","article-title":"Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease","volume":"7","author":"Chapman","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.01.003_bib19","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2017.01.003_bib20","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1053\/j.ajkd.2005.08.026","article-title":"Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP)","volume":"46","author":"O\u2019Neill","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2017.01.003_bib21","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","article-title":"Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial","volume":"382","author":"Caroli","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2017.01.003_bib22","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1056\/NEJMoa1402686","article-title":"Angiotensin blockade in late autosomal dominant polycystic kidney disease","volume":"371","author":"Torres","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2017.01.003_bib23","unstructured":"Interactive Tool for Computation of Hazard Ratio According to eGFR, TKV and Age. Available at: https:\/\/pharmacometrics.shinyapps.io\/KIreports. Accessed December\u00a030, 2016."},{"key":"10.1016\/j.ekir.2017.01.003_bib24","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1681\/ASN.2015010016","article-title":"The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease","volume":"27","author":"Cornec-Le Gall","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.01.003_bib25","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1681\/ASN.2006080835","article-title":"Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease","volume":"17","author":"Harris","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.01.003_bib26","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1681\/ASN.2015050583","article-title":"Predicted mutation strength of nontruncating PKD1 mutations aids genotype-phenotype correlations in autosomal dominant polycystic kidney disease","volume":"27","author":"Heyer","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.01.003_bib27","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ekir.2017.02.011","article-title":"A drug development tool for trial enrichment in patients with autosomal dominant polycystic kidney disease","volume":"2","author":"Perrone","year":"2017","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2017.01.003_bib28","unstructured":"US Food and Drug Administration. Qualification of Biomarker\u2014Total Kidney Volume in Studies for Treatment of Autosomal Dominant Polycystic Kidney Disease. Available at: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM458483.pdf. Accessed December\u00a030, 2016."},{"key":"10.1016\/j.ekir.2017.01.003_bib29","unstructured":"European Medicines Agency. Qualification opinion. Total Kidney Volume (TKV) as a prognostic biomarker for use in clinical trials evaluating patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Regulatory_and_procedural_guideline\/2015\/11\/WC500196569.pdf. Accessed December\u00a030, 2016."}],"updated-by":[{"DOI":"10.1016\/j.ekir.2018.05.006","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000}}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024917300037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024917300037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T12:19:40Z","timestamp":1568722780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024917300037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S2468024917300037"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2017.01.003","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ekir.2018.05.006","asserted-by":"object"}]},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in\u00a0Patients With Autosomal Dominant Polycystic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2017.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2017.02.011","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2017.04.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}